The second market application for Eli Lilly’s IL-17A antibody Taltz (ixekizumab) was accepeted by the NMPA. According the information of the clincial trials, the indication may be radiologically positive axial spondyloarthritis (axSpA).
axSpA is a chronic autoimmune diseases Ixekizumab is an inhibitor targeting interleukin 17A (IL-17A) that selectively binds IL-17A and inhibits its interaction with the IL-17 receptor. It inhibits the release of pro-inflammatory cytokines and chemokines by inhibiting IL-17 receptor-mediated signaling pathways, thereby alleviating symptoms of inflammatory diseases.
Based on the registration information on the ClinicalTrials.gov website, Eli Lilly is currently conducting a 16-week multicenter, randomized, double-blind and placebo-controlled Phase III clinical trial that is designed to evaluate the efficacy and safety of Ixekizumab in patients with radiologically positive axSpA in China.
Ixekizumab got its first market approved in China in September 2019 for the treatment of adult patients with moderate to severe plaque psoriasis.
Novartis’ Cosentyx, UCB’s Bimzelx and another three home-grown IL-17A antibodies are also in clincial development for axSpA patients in China.